Tyrosine Kinases and Endothelial Homeostasis in Pulmonary Arterial Hypertension: Too Hot to Handle?
作者信息
Bogaard Harm Jan, Aman Jurjan
机构信息
Pulmonary Diseases Amsterdam UMC, Locatie VUMC Amsterdam, the Netherlands.
出版信息
Am J Respir Cell Mol Biol. 2022 Aug;67(2):147-149. doi: 10.1165/rcmb.2022-0122ED.
Abstract
摘要
相似文献
1
Tyrosine Kinases and Endothelial Homeostasis in Pulmonary Arterial Hypertension: Too Hot to Handle?酪氨酸激酶与肺动脉高压中的内皮稳态：难以应对？
Am J Respir Cell Mol Biol. 2022 Aug;67(2):147-149. doi: 10.1165/rcmb.2022-0122ED.
2
Too hot? Too cold? Wnt signalling in pulmonary arterial hypertension: can we treat it "just right"?太热？太冷？肺动脉高压中的Wnt信号传导：我们能将其“恰到好处”地治疗吗？
Eur Respir J. 2023 Jun 8;61(6). doi: 10.1183/13993003.00504-2023. Print 2023 Jun.
3
Special delivery: Engineered endothelial cells for pulmonary arterial hypertension.特殊递送：用于肺动脉高压的工程化内皮细胞
Respirology. 2019 Nov;24(11):1042-1043. doi: 10.1111/resp.13686. Epub 2019 Aug 19.
4
Hungry for Chloride: Reprogramming Endothelial Cell Metabolism in Pulmonary Arterial Hypertension.对氯离子的渴望：肺动脉高压中内皮细胞代谢的重编程
Am J Respir Cell Mol Biol. 2023 Jan;68(1):11-12. doi: 10.1165/rcmb.2022-0386ED.
5
"Rehab for all!" Is it too early in pulmonary arterial hypertension?“全民康复！”对于肺动脉高压而言，现在提这个是否为时过早？
Eur Respir J. 2019 Nov 7;54(5). doi: 10.1183/13993003.01558-2019. Print 2019 Nov.
6
Pulmonary Arterial Hypertension: Too Complex for Physicians, Too Complex for ICD Diagnosis Codes.肺动脉高压：对医生来说过于复杂，对国际疾病分类诊断编码来说也过于复杂。
Chest. 2019 May;155(5):1077. doi: 10.1016/j.chest.2019.01.029.
7
Nets, pulmonary arterial hypertension, and thrombo-inflammation.网状内皮系统、肺动脉高压和血栓炎症。
J Mol Med (Berl). 2022 May;100(5):713-722. doi: 10.1007/s00109-022-02197-0. Epub 2022 Apr 20.
8
Tyrosine kinase inhibitors in pulmonary arterial hypertension: a double-edge sword?肺动脉高压中的酪氨酸激酶抑制剂：一把双刃剑？
Semin Respir Crit Care Med. 2013 Oct;34(5):714-24. doi: 10.1055/s-0033-1356494. Epub 2013 Sep 13.
9
Endothelial CFTR dysfunction and its involvement in the pathogenesis of pulmonary arterial hypertension.内皮细胞囊性纤维化跨膜传导调节因子功能障碍及其在肺动脉高压发病机制中的作用。
Eur Respir J. 2021 Aug 19;58(2). doi: 10.1183/13993003.01645-2021. Print 2021 Aug.
10
The Pathobiology of Pulmonary Arterial Hypertension.肺动脉高压的病理生理学。
Cardiol Clin. 2022 Feb;40(1):1-12. doi: 10.1016/j.ccl.2021.08.001.
本文引用的文献
1
Loss of cAbl Tyrosine Kinase in Pulmonary Arterial Hypertension Causes Dysfunction of Vascular Endothelial Cells.肺动脉高压中 cAbl 酪氨酸激酶的缺失导致血管内皮细胞功能障碍。
Am J Respir Cell Mol Biol. 2022 Aug;67(2):215-226. doi: 10.1165/rcmb.2021-0332OC.
2
CBL knockdown protects cardiomyocytes against hypoxia-reoxygenation injury by downregulating GRB2 expression.CBL基因敲低通过下调GRB2表达保护心肌细胞免受缺氧复氧损伤。
Exp Ther Med. 2022 Feb;23(2):188. doi: 10.3892/etm.2022.11111. Epub 2022 Jan 3.
3
c-Abl Inhibitors as Disease-Modifying Therapies for Parkinson's Disease: Gaps and Opportunities.c-Abl抑制剂作为帕金森病的疾病修饰疗法：差距与机遇
Mov Disord. 2022 Jan;37(1):3-5. doi: 10.1002/mds.28907.
4
Positioning imatinib for pulmonary arterial hypertension: A phase I/II design comprising dose finding and single-arm efficacy.伊马替尼用于肺动脉高压的定位研究：一项包含剂量探索和单臂疗效的I/II期设计。
Pulm Circ. 2021 Oct 17;11(4):20458940211052823. doi: 10.1177/20458940211052823. eCollection 2021 Oct-Dec.
5
Novel Mechanisms Targeted by Drug Trials in Pulmonary Arterial Hypertension.肺动脉高压药物试验的新靶点。
Chest. 2022 Apr;161(4):1060-1072. doi: 10.1016/j.chest.2021.10.010. Epub 2021 Oct 13.
6
Cellular senescence impairs the reversibility of pulmonary arterial hypertension.细胞衰老损害肺动脉高压的可逆性。
Sci Transl Med. 2020 Jul 29;12(554). doi: 10.1126/scitranslmed.aaw4974.
7
The hallmarks of severe pulmonary arterial hypertension: the cancer hypothesis-ten years later.严重肺动脉高压的特征：癌症假说十年后。
Am J Physiol Lung Cell Mol Physiol. 2020 Jun 1;318(6):L1115-L1130. doi: 10.1152/ajplung.00476.2019. Epub 2020 Feb 5.
8
c-Abl regulates YAPY357 phosphorylation to activate endothelial atherogenic responses to disturbed flow.c-Abl 调节 YAPY357 磷酸化以激活内皮细胞对血流紊乱的动脉粥样硬化反应。
J Clin Invest. 2019 Mar 1;129(3):1167-1179. doi: 10.1172/JCI122440. Epub 2019 Feb 11.
9
Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives.肺动脉高压的病理学和病理生物学：现状和研究展望。
Eur Respir J. 2019 Jan 24;53(1). doi: 10.1183/13993003.01887-2018. Print 2019 Jan.
10
Pulmonary arterial hypertension induced by tyrosine kinase inhibitors.酪氨酸激酶抑制剂所致的肺动脉高压
Curr Opin Pulm Med. 2017 Sep;23(5):392-397. doi: 10.1097/MCP.0000000000000412.
Zotero 插件